Literature DB >> 8298556

Pulmonary function changes 100 days and one year after bone marrow transplantation.

M Badier1, C Guillot, S Delpierre, P Vanuxem, D Blaise, D Maraninchi.   

Abstract

The pulmonary function of patients receiving autologous or allogeneic bone marrow transplantation (BMT) was studied before, 100 days after and 1 year after BMT. The 117 patients studied before transplantation showed a slight reduction in average total lung capacity (TLC) and transfer coefficient (KCO). These reductions were related to haematological disease, previous pulmonary disease or irradiation, or use of toxic lung chemotherapy. Studies 100 days after BMT showed TLC and KCO decreases of 5% and 8%, respectively. These decreases were related to different factors in autologous and allogeneic BMT. The results were influenced by previous pulmonary status in autologous BMT patients and the occurrence of GVHD in allogeneic BMT patients. Seventy patients underwent pulmonary function testing 1 year after BMT. The decrease in TLC values was greater in autologous BMT than in allogeneic BMT patients (107 +/- 3% to 100 +/- 3% versus 113 +/- 3% to 112 +/- 2%, respectively) although TLC remained normal in both groups. KCO values dropped significantly in both populations. Relapse of the initial disease was an important factor impairing lung function in the autologous group. TLC and KCO changes were strongly related to mortality in both groups. These results emphasise the need for frequent pulmonary function tests after BMT to detect and quantify lung function changes.

Entities:  

Mesh:

Year:  1993        PMID: 8298556

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Clinical impact of pre-transplant pulmonary impairment on survival after allogeneic hematopoietic stem cell transplantation.

Authors:  Kazuhiko Kakihana; Kazuteru Ohashi; Yuka Hirashima; Yutaka Murata; Takeshi Kobayashi; Takuya Yamashita; Hisashi Sakamaki; Hideki Akiyama
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

2.  Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.

Authors:  Gregory A Yanik; Shin Mineishi; John E Levine; Carrie L Kitko; Eric S White; Mark T Vander Lugt; Andrew C Harris; Thomas Braun; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-10       Impact factor: 5.742

3.  Lung function after allogeneic bone marrow transplantation for leukaemia or lymphoma.

Authors:  K Nysom; K Holm; B Hesse; C S Ulrik; N Jacobsen; H Bisgaard; H Hertz
Journal:  Arch Dis Child       Date:  1996-05       Impact factor: 3.791

4.  Lung function and long-term complications after allogeneic hematopoietic cell transplant.

Authors:  Eric C Walter; Mauricio Orozco-Levi; Alba Ramirez-Sarmiento; Afonso Vigorito; Paulo V Campregher; Paul J Martin; Mary E Flowers; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-17       Impact factor: 5.742

5.  Influence of pretransplantation restrictive lung disease on allogeneic hematopoietic cell transplantation outcomes.

Authors:  Alba Ramirez-Sarmiento; Mauricio Orozco-Levi; Eric C Walter; Margaret A Au; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-23       Impact factor: 5.742

6.  Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?

Authors:  Jason W Chien; Keith M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2009-04       Impact factor: 5.742

Review 7.  Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.

Authors:  G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.